Extended Data Fig. 6: Heatmap depicts enrichment scores of gene sets as defined in the Nanostring immune-exhaustion panel.
Transcriptomic analysis of baseline tumor biopsies was performed in 13 patients, of whom 5 had ongoing response (CR, n = 5), 6 relapsed (CR, n = 5), and 2 were non-responders at the data cutoff date. AKT, protein kinase B; AP-1, activator protein 1; BCR, B cell receptor signaling; CR, complete response; CTLA4, cytotoxic T-lymphocyte associated protein 4; DAP12, DNAX-activating protein of 12 kDa; GSVA, gene set variation analysis score; IL, interleukin; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; NF-kB, nuclear factor kappa B; NK, natural killer; PD, progressive disease; PD1, programmed cell death protein 1; PI3K, phosphoinositide-3 kinase; PPAR, peroxisome proliferator-activated receptor; PR, partial response; RAR, retinoic acid receptor; SD, stable disease; STAT, signal transducer and activator of transcription; TCR, T cell receptor; TGF, transforming growth factor; TLR, toll-like receptor; TNF, tumor necrosis factor.
